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extraordinary stability and provide a new strategy
for zirconium-89-based radiopharmaceutical
development†‡
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Brandie M. Ehrmann,d Marcus Wright,c Ulrich Bierbachc and Thaddeus J. Wadas*a
We report our initial investigations into the use of tetraazamacrocycles as zirconium-89 chelators. We
describe the synthesis and complete characterization of several Zr tetraazamacrocycle complexes, and
definitively describe the first crystal structure of zirconium 1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid (Zr–DOTA) using single crystal X-ray diffraction analysis. After evaluating several
radioactive analogs, we found that 89Zr–DOTA is superior to 89Zr–DFO, the only 89Zr-complex to be
used clinically in 89Zr-radiopharmaceutical applications. Finally, we provide a rationale for the
unanticipated and extraordinary stability of these complexes in vitro and in vivo. These results may
inform the development of safer and more robust immuno-PET agents for precision medicine applications.Introduction
Zirconium-89 (89Zr: (t1/2 ¼ 78.4 h, b+: 22.8%, Eb+max ¼ 901 keV;
EC: 77%, Eg ¼ 909 keV)) is a positron-emitting radionuclide
currently being tested in over 30 clinical trials involving
monoclonal antibodies (mAbs); its radioactive half-life
complements the biological half-life of a circulating antibody
in vivo.1 Standard practice within the radiopharmaceutical
industry requires 89Zr to be attached to an antibody through
desferrioxamine (DFO) or its analogs, which are derivatives of
the iron chelator desferral, a growth-promoting agent secreted
by Streptomyces pilosus.2,3 Despite the widespread use of DFO
in 89Zr-immuno-PET applications, the unsaturated coordina-
tion sphere of 89Zr–DFO is believed to be responsible for its
observed instability in preclinical animal models,4–6 and
signicant effort has been expended to develop improved
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hemistry 2017Tetraazamacrocycles such as 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) remain a largely unexplored
class of ligands due to a perceived inability to form stable
89Zr-complexes.20,22–24 Although only anecdotal evidence has
appeared in the literature, instability is believed to arise from
chelation by the fourmacrocycle nitrogen atoms and four oxygen
atoms of the pendant arms rather than eight oxygen donors,
which are believed to be preferred by the oxophilic 89Zr4+ ion.23
As a result, little is known regarding their Zr coordination
chemistry or use in 89Zr-radiopharmaceutical development.
Despite well-reasoned arguments to the contrary,20,22–24 it seemed
reasonable to posit that tetraazamacrocycles would be useful in
89Zr-radiopharmaceutical applications, since several Zr–cyclam
complexes have been described previously.25,26 Additionally, we
reasoned that their use would be advantageous since (1) they
demonstrate enhanced stability over acyclic ligands due to the
macrocyclic effect; (2) various functional groups can be intro-
duced into the macrocycle's backbone or pendant arms to
modulate the ligand's stereo- and coordination chemistry; (3)
bifunctional chelators derived from these ligands allow them to
be conjugated to various peptides, proteins, and antibodies; and
(4) they have been used successfully in a number of radiophar-
maceutical applications and clinical trials.
Here we document our initial investigations into the use of
tetraazamacrocycles as 89Zr-chelators. We describe the synthesis
and complete characterization of Zr–DOTA, Zr–DOTAM, and
Zr–DOTP (Fig. 1), and describe the rst crystal structure of
Zr–DOTA, which reveals a saturated coordination sphere around
the Zr4+ ion. Finally, we evaluate the radioactive analogs in vitro
and in vivo, and show that 89Zr–DOTA demonstrates behaviourChem. Sci., 2017, 8, 2309–2314 | 2309
Fig. 1 Structures of tetraazamacrocyclic ligands, desferral (DFO), and
their 89Zr-complexes.
Fig. 2 Crystal structure of Zr–DOTA.‡ Thermal ellipsoids are drawn at
the 50% probability level; only one of the crystallographically-inde-
pendent Zr centers is shown and a partial atomic labeling scheme is
provided. The disordered Zr center, disordered solvent molecules, and
hydrogen atoms are omitted for clarity.
























































































View Article Onlinethat is superior to 89Zr–DFO. To the best of our knowledge, this is
the rst report to evaluate tetraazamacrocycles as 89Zr-chelators
and to provide a rationale for their exceptional and unpredicted
in vivo behaviour.
Experimental methods
Full experimental details are presented in the ESI.‡
Results and discussion
During initial syntheses of the nonradioactive complexes, we
observed poor reactivity when the respective ligands were
reacted with zirconium oxalate (Zr(ox)2), which demonstrates
poor solubility in a variety of solvents. Thus, we used either
Zr(IV) acetylacetonate (Zr(AcAc)4) or ZrCl4 as zirconium sources
with subsequent synthetic strategies modied from the litera-
ture.11,16,27 Accordingly, nonradioactive Zr–DOTA (Scheme S1‡),
Zr–DOTP (Scheme S2‡) and Zr–DOTAM (Scheme S3‡) were
prepared in excellent yields and all were fully characterized by
HPLC, NMR spectroscopy, and HR-MS analyses (Fig. S1–S20‡).
While single crystals of all complexes were obtained, only those
of Zr–DOTA were suitable for single crystal X-ray diffraction
analysis.
In our hands, single crystal X-ray diffraction of Zr–DOTA
revealed 2 crystallographically-independent molecules in the
asymmetric unit with C4 symmetry. One of the Zr sites is
disordered (68%/32%) over 2 sites along the 4-fold axis. The
ordered site at Zr1 is depicted in Fig. 2 and complete crystal-
lographic parameters, data collection and renement infor-
mation are included in the ESI.‡ All four macrocycle nitrogen
atoms and acetate pendant arms participate in Zr4+ ion coor-
dination to form an octa-coordinate complex, which may be
the key to the relationship between the complex's structure
and its unanticipated in vivo behaviour (vide infra). The
Zr–DOTA complex exhibits a compressed, square anti-pris-
matic geometry. This is not unusual, since Zr tetraazamacro-
cycle complexes exhibit varying geometries dictated by the
additional ligands that occupy the coordination sites not
occupied by the nitrogen atoms of the macrocycle.25,26,28 The
perpendicular distance from the metal center to the plane
described by the 4 acetate-containing pendant arms of the
macrocycle is 1.004(3) Å, and the perpendicular distance from2310 | Chem. Sci., 2017, 8, 2309–2314the metal center to the plane described by the 4 nitrogens of
the macrocycle is 1.310(4) Å. The DOTA ligand displays a low-
symmetry saddle-like conformation similar to that of metal–
dibenzotetramethytetraaza[14]annulene complexes described
by De Angelis and co-workers.29 This conformation is most
pronounced with metal complexes demonstrating d0 electron
congurations, which lack crystal-eld stabilization.29 The
average Zr–ligand bond lengths and bond angles are compa-
rable to those observed in structurally characterized Zr
complexes containing hydroxamate, phenoxyamine, salophen,
or cyclam ligands.25,26,28,30–33
Aer completing synthesis and characterization of the refer-
ence complexes, we attempted to radiolabel each ligand using
89Zr(ox)2 and procedures established for preparation of
89Zr–DFO.5 However, radiochemical yields were poor (Scheme S4
and Table S6‡). Thus, we used 89ZrCl4 as a radioactive
precursor,5 and observed that DOTA, DOTAM, and DOTP were
quantitatively radiolabeled within 45 minutes at 90 C (Scheme
S5‡). Optimized radiochemical synthesis conditions are pre-
sented in Table S7.‡ The radiochemical yield and purity of all
89Zr complexes were conrmed by radio-TLC (Fig. S25, S27 and
S29‡) or radio-HPLC (Fig. S26 and S28‡). The specic activity (As)
for each radiometal complex is in good agreement with the As of
other 89Zr-complexes reported in the literature.9,15 The surprising
differences in reactivity observed for 89Zr(ox)2 and
89ZrCl4 with
tetraazamacrocycles are most likely dictated by the 89Zr species
present in solution. Nonradioactive Zr(ox)2 is a highly stable
complex, even under highly acidic conditions and at very low
molar concentrations.34 Accordingly, the oxalate anion's ability
to form a stable 89Zr-complex in aqueous media effectively
competes with the tetraazamacrocycle ligand, resulting in
reduced 89Zr-tetraazamacrocycle complex formation. On the
other hand, natural ZrCl4 (like other highly charged, oxophilic
metal halides) readily undergoes aquation in solution to form
hydroxo- and oxo-bridged species.35 It is reasonable that 89ZrCl4
would demonstrate a similar behaviour.34 Thus, in the absence
of an oxalate ligand, 89Zr–tetraazamacrocycle complex formationThis journal is © The Royal Society of Chemistry 2017
























































































View Article Onlineis favoured over the formation of 89ZrOH species when 89ZrCl4 is
added to a buffered solution of the macrocycle.
Since tetraazamacrocycles are considered poor 89Zr-chela-
tors,20,22–24 we evaluated the in vitro stability of 89Zr–DOTA,
89Zr–DOTAM, and 89Zr–DOTP by challenging them with excess
EDTA, high concentrations of biologically relevant metal ions,
or human serum proteins. 89Zr–DOTA did not undergo trans-
chelation, with a 100-, 500-, and 1000-fold excess of EDTA at pH
5 or pH 7 over 7 days. In contrast, 89Zr–DFO completely lost
metal ions aer 3 h incubation, with a 1000-fold excess of EDTA
at pH 5. Based upon our EDTA challenge studies, the order of
89Zr-complex stability can be described as 89Zr–DOTA [
89Zr–DOTP > 89Zr–DOTAM > 89Zr–DFO (Table S8‡).
Tetraazamacrocycles can chelate numerous, biologically
relevant metal cations, and this property can potentially create
a second mechanism for 89Zr4+ ion dissociation from its
chelator in vivo.1 To assess the ability of the Zr complexes to
resist demetallation by another metal cation, we performed
metal competition studies, in which we mixed the radiometal
complex with an excess concentration of metal salts in aqueous
buffer. We observed no demetallation of 89Zr–DOTA over the
7 day experiment (Table S9‡). In contrast, 89Zr–DFO remained
only 33.9% and 72.6% intact, respectively, when challenged
with Fe3+ ions or Ga3+ ions. The overall order of 89Zr-complex
stability based upon these studies mirrored our results in the
EDTA challenge experiments, further demonstrating the robust
stability of Zr–tetraazamacrocycle complexes.
We then evaluated the in vivo behaviour of 89Zr–DOTA,
89Zr–DOTP, and 89Zr–DOTAM in acute biodistribution studies.
Results are shown in Tables S12–S14.‡ Mice receiving
89Zr–DOTAM retained elevated levels of radioactivity in liver and
spleen tissues, which was not excreted over the 72 h experiment.
In vitro, 89Zr–DOTAM aggregated and precipitated out of solu-
tion unless a low concentration of surfactant was included to
stabilize the complex. While surfactant was used in the injec-
tion formulation for biodistribution studies, it is hypothesized
that once in the blood stream, 89Zr–DOTAM aggregates with
serum proteins, which are deposited in these tissues during
circulation. We could not identify the radioactive species, and
thus we did not evaluate 89Zr–DOTAM further.
Mice intravenously injected with 89Zr–DOTA retained
signicantly less radioactivity in their liver, kidney, and bone
tissue compared to mice injected with 89Zr–DOTP at 72 h post-
injection (89Zr–DOTA vs. 89Zr–DOTP: % ID per g  SD, p value)
(blood, 0.0003  0.001 vs. 0.0005  0.001, 0.39; liver, 0.021 
0.002 vs. 0.036 0.002, <0.0001; kidney, 0.078 0.009 vs. 0.32
0.045, <0.0001; bone, 0.025  0.009 vs. 2.63  0.12, <0.0001).
Higher retention of 89Zr–DOTP was predicted by the in vitro
kinetic stability results, and may suggest transchelation to
serum proteins or reduced stability in the presence of the lower
pH environments that may exist in Kupffer cell lysosomes or the
kidney.36,37 Retention of radioactivity in bones of mice receiving
89Zr–DOTP may be caused by a number of factors, e.g. residu-
alization of 89Zr transchelated by hydroxylapatite, or adsorption
of the intact complex in the bone matrix due to the inuence of
the four phosphate-containing pendant arms of the 89Zr–DOTP
complex. The latter phenomenon was observed with otherThis journal is © The Royal Society of Chemistry 2017radiometal–DOTP complexes.1 Fewer phosphate-containing
pendant arms may reduce bone retention, and studies of
phosphate-containing 64Cu–tetraazamacrocycle complexes
show that this strategy reduces the amount of radioactivity
retained in bone tissue.38
We then compared the performance of 89Zr–DOTA and
89Zr–DFO (Fig. S37‡). Each had similar blood excretion proles,
but animals injected with 89Zr–DOTA had lower radioactivity
retention in liver, kidney, and bone tissue at 72 h post-injection
(89Zr–DOTA vs. 89Zr–DFO: % ID per g  SD, p value) (blood,
0.0003 0.0008 vs. 0.0003 0.0005, 1.00; liver, 0.021 0.002 vs.
0.066  0.009, <0.0001; kidney, 0.078  0.009 vs. 0.69  0.098,
<0.0001; bone, 0.025  0.009 vs. 0.079  0.014, <0.0001).
Interestingly, while radioactivity retention in bone tissue of
mice injected with 89Zr–DFO increases over time, radioactivity
retention in bone tissue of mice receiving 89Zr–DOTA remained
low, with no statistically signicant changes at any time point.
One possible explanation for these observations may be the
tetraazamacrocycle's ability to form an octa-coordinate complex
with the 89Zr4+ ion. The saturated coordination sphere plus the
four hard oxygen donor groups are believed to produce
a complex that remains resistant to chemical, biological, and
physical factors that may destabilize a radiometal complex in
vivo. However, it is unknown if resistance to these forces will be
maintained when 89Zr–DOTA is incorporated into an antibody
conjugate. These studies are currently underway in our
laboratory.
Normal mice were injected with 89Zr–DFO and 89Zr–DOTA
and dynamic PET imaging done from 0–60 minutes, followed by
static imaging at 2, 4, and 24 h aer injection. Both radiometal
complexes exhibited a similar excretion prole based on the
amount of radioactivity in the blood pool and the liver during
rst 60 minutes (Fig. 3, S38, and S39‡). Radioactivity in the
kidney and bone was much lower in mice receiving 89Zr–DOTA
compared to 89Zr–DFO, suggesting a better excretion prole
from these tissues (see Fig. 3 and S38‡). Both 89Zr–DFO and
89Zr–DOTA are excreted renally, with elevated levels of radioac-
tivity in the kidneys and bladder at early time points. However,
by 4 h, nearly all the radioactivity was excreted from mice that
received 89Zr–DOTA, and aer 24 h, radioactivity was barely
above background levels. By contrast, more radioactivity accu-
mulated in the kidneys of mice injected with 89Zr–DFO at 4 h,
and they were still visible in static images acquired aer 24 h.
Results of region-of-interest analysis on the data acquired during
the static imaging sessions further corroborate our bio-
distribution studies, which suggest that the in vivo behavior of
89Zr–DOTA is superior to 89Zr–DFO (Table S16‡). However, only
metabolism studies will provide denitive proof of the radioac-
tive species retained or excreted. Accordingly, we are currently
performing such studies to examine the fates of 89Zr–oxalate,
89ZrCl4,
89Zr–DFO, and 89Zr–DOTA in mouse tissues.
Based on these unexpected observations, we attempted to
place our results in context by comparing them with published
studies of other 89Zr-chelators (Tables S17–S19‡). Variability in
study designs or unreported data prevented direct comparisons
among all ligand classes, but comparisons were made when
possible.Chem. Sci., 2017, 8, 2309–2314 | 2311
Fig. 3 PET maximum-intensity projection images comparing 89Zr–DOTA and 89Zr–DFO. 89Zr–DOTA undergoes more efficient renal excretion
than 89Zr–DFO. By 4 h post-injection, most activity associated with 89Zr–DOTA was excreted into the bladder; by 24 h post-injection, very little
activity remained. Mice injected with 89Zr–DFO retained significantly more radioactivity in their kidneys at 4 h and 24 h post-injection.
























































































View Article OnlineIn vitro data suggest that 89Zr–DOTA was more resistant to
EDTA challenge than 89Zr–TAFC,39 which was 97% intact aer
7 days exposure to 1000 fold EDTA (pH 7). Additionally, metal ion
competition studies suggest that 89Zr–DOTA was more resistant
to exogenous metal challenge than either 89Zr–HOPO or
89Zr–CP256.9,14 When exposed to Fe3+ ions, only 83% of the
89Zr–HOPO complex was still intact aer 7 days, and only 14% of
89Zr–CP256 remained intact aer 20 minutes. Finally, in vivo
biodistribution data were also examined at 24 h post-injection.
Mice injected with 89Zr-TAM-1, 89Zr-TAM-2, and 89Zr-2,3-HOPO
retained 26, 145, and 92 fold more radioactivity, respectively, in
kidney tissue than mice injected with 89Zr–DOTA.15,19 In the same
ligand series, mice injected with the corresponding radiometal
chelates retained 2.6, 7.6 and 7.6 fold more radioactivity, respec-
tively in bone tissue than did animals receiving 89Zr–DOTA.15,19
Also, approximately 5 and 16 fold more radioactivity was observed
in the bone tissue of animals injected with 89Zr–HOPO and
89Zr–L4, respectively.9,10 This limited comparison of in vitro and in
vivo behaviour suggests that 89Zr–DOTA is the most stable
89Zr-complex reported to date, and its apparent resilience to
perturbation in vitro and in vivo is remarkable and unexpected.
Although the elevated temperature needed to synthesize 89Zr
tetraazamacrocycle complexes may be considered a limitation
of this work, it should not prohibit exploration of these radio-
metal chelates in immuno-PET applications, since various
methods can be used to circumvent this temperature require-
ment and prepare useful 89Zr-radiopharmaceuticals.40–42
Furthermore, the use of 89ZrCl4 as a
89Zr-source allows access to
ultra-stable 89Zr-complexes, previously believed to be inacces-
sible or unstable. The synthetic methodologies we describe here
can facilitate systematic study of 89Zr coordination chemistry
using inorganic chemistry, radiochemistry and molecular
imaging techniques to elucidate how to create 89Zr-radiophar-
maceuticals with excellent stability in vivo. While many ligands
have been developed to chelate 89Zr, a systematic study among
ligand classes has not been described in the literature. Just as
a systematic study of tetraazamacrocycles beneted 64Cu
radiopharmaceutical development and led to the ultra-stable2312 | Chem. Sci., 2017, 8, 2309–2314cross-bridged chelators,43–46 similar advances could be accom-
plished based on systematic study of these 89Zr-tetraazama-
crocycle complexes. Finally, clinicians are increasingly using
89Zr–DFO–mAbs in dosimetry and therapeutic planning before
targeted systemic radiotherapy.47–51 Since DOTA can effectively
chelate 89Zr and other therapeutic radionuclides,52–54 it is
plausible to imagine that one DOTA–mAb conjugate would be
needed to accomplish dosimetry and radiotherapy with 89Zr and
a therapeutic radionuclide, respectively. This approach may
increase dosimetric accuracy, reduce regulatory burden, and
minimize costs associated with cGMP-compliant radiophar-
maceutical development, so that these precision medicine
applications may be used more effectively in the future.
Conclusions
This report is the rst to describe the structural characterization
of Zr–DOTA using single-crystal X-ray diffraction and the use of
tetraazamacrocycles as 89Zr-chelators. In all studies, 89Zr–DOTA
demonstrated superior in vivo behaviour compared to
89Zr–DFO, which is considered the “gold standard” in clinical
89Zr-radiopharmaceutical development. These results refute
current thinking regarding the use of tetraazamacrocycles as
89Zr-chelators, and may provide a way to enhance development
of radiolabeled agents for precision medicine applications.
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